MA43397A - Pyroglutamate de vortioxetine - Google Patents

Pyroglutamate de vortioxetine

Info

Publication number
MA43397A
MA43397A MA043397A MA43397A MA43397A MA 43397 A MA43397 A MA 43397A MA 043397 A MA043397 A MA 043397A MA 43397 A MA43397 A MA 43397A MA 43397 A MA43397 A MA 43397A
Authority
MA
Morocco
Prior art keywords
vortioxetine pyroglutamate
vortioxetine
pyroglutamate
Prior art date
Application number
MA043397A
Other languages
English (en)
Inventor
Kim Lasse Christensen
Diego Heidi Lopez De
Rene Holm
Jens Kateb
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55963369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA43397A publication Critical patent/MA43397A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA043397A 2015-05-13 2016-05-11 Pyroglutamate de vortioxetine MA43397A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201500284 2015-05-13

Publications (1)

Publication Number Publication Date
MA43397A true MA43397A (fr) 2018-03-21

Family

ID=55963369

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043397A MA43397A (fr) 2015-05-13 2016-05-11 Pyroglutamate de vortioxetine

Country Status (43)

Country Link
US (2) US10287261B2 (fr)
EP (1) EP3294719B1 (fr)
JP (1) JP6731001B2 (fr)
KR (1) KR102551429B1 (fr)
CN (1) CN107567440B (fr)
AR (1) AR104591A1 (fr)
AU (1) AU2016259762B2 (fr)
BR (1) BR112017024039B8 (fr)
CA (1) CA2984615C (fr)
CL (1) CL2017002844A1 (fr)
CO (1) CO2017011295A2 (fr)
CR (1) CR20170506A (fr)
CY (1) CY1121171T1 (fr)
DK (1) DK3294719T3 (fr)
DO (1) DOP2017000260A (fr)
EA (1) EA032363B1 (fr)
EC (1) ECSP17074919A (fr)
ES (1) ES2709362T3 (fr)
GE (1) GEP20197020B (fr)
HK (1) HK1252099B (fr)
HR (1) HRP20190089T1 (fr)
HU (1) HUE042893T2 (fr)
IL (1) IL255466B (fr)
JO (1) JO3456B1 (fr)
LT (1) LT3294719T (fr)
MA (1) MA43397A (fr)
ME (1) ME03312B (fr)
MX (1) MX2017014390A (fr)
MY (1) MY184965A (fr)
PE (1) PE20180039A1 (fr)
PH (1) PH12017502028A1 (fr)
PL (1) PL3294719T3 (fr)
PT (1) PT3294719T (fr)
RS (1) RS58263B1 (fr)
RU (1) RU2713889C2 (fr)
SI (1) SI3294719T1 (fr)
SV (1) SV2017005560A (fr)
TN (1) TN2017000453A1 (fr)
TR (1) TR201901228T4 (fr)
TW (1) TWI700276B (fr)
UA (1) UA120779C2 (fr)
WO (1) WO2016180870A1 (fr)
ZA (1) ZA201707337B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524682A (ja) 2016-07-01 2019-09-05 ハー・ルンドベック・アクチエゼルスカベット 抗うつ作用の速い発現のためのボルチオキセチン投与計画
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
EP3582759A4 (fr) * 2017-02-17 2021-01-06 Unichem Laboratories Ltd Composition pharmaceutique bioéquivalente de bromhydrate de vortioxétine
PL3532457T3 (pl) * 2017-07-31 2020-10-19 Small Pharma Ltd Postacie krystaliczne hydroksynorketaminy
GB201715950D0 (en) 2017-10-02 2017-11-15 Croda Int Plc Gel composition comprising a phase change material
WO2021198778A1 (fr) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-diméthylphénylsulfanyl)-phényl]pipérazine pour la prévention ou le traitement de l'émoussement émotionnel

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1006728A (en) * 1962-12-31 1965-10-06 Mundipharma Ag Amine salts of pyrrolidone carboxylic acid
JPS6160620A (ja) 1984-09-03 1986-03-28 Teijin Ltd ピログルタミン酸エステル類を含有する医薬品組成物
US4780667A (en) 1985-06-25 1988-10-25 Hewlett-Packard Company Magnetostatic wave delay line discriminator with automatic quadrature setting and automatic calibration
FR2694194B1 (fr) 1992-07-31 1994-11-04 Health Business Dev Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel.
EP0918513B1 (fr) 1996-08-15 2000-12-06 Losan Pharma GmbH Medicament a administration orale facile a avaler
US6436946B1 (en) * 1997-05-02 2002-08-20 Morris A. Mann Xanthine-containing compositions for oral administration and uses related thereto
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ES2370729T3 (es) 2004-05-11 2011-12-22 Egalet Ltd. Forma farmacéutica hinchable que comprende goma gellan.
WO2007144005A1 (fr) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1-[2-(2, 4-diméthylphénylsulfanyl)-phényl]pipérazine comme composé présentant une activité sur la sérotonine, 5-ht3 et 5-ht1a pour le traitement du déficit cognitif
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
JP5722879B2 (ja) 2009-04-24 2015-05-27 ハー・ルンドベック・アクチエゼルスカベット １−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジンの塩の液体製剤
PL2470166T3 (pl) 2009-08-24 2013-11-29 H Lundbeck As Nowe kompozycje 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny
EP2564838A4 (fr) * 2010-04-30 2014-06-04 Takeda Pharmaceutical Comprimé à délitage intestinal
US9499504B2 (en) * 2012-09-19 2016-11-22 Sandoz Ag Crystalline form of vortioxetine hydrobromide
GEP201706749B (en) 2013-02-22 2017-10-10 H Lundbeck As Vortioxetine manufacturing process

Also Published As

Publication number Publication date
US11279682B2 (en) 2022-03-22
US20190210987A1 (en) 2019-07-11
DK3294719T3 (en) 2019-02-25
ME03312B (fr) 2019-10-20
SI3294719T1 (sl) 2019-03-29
KR20180006909A (ko) 2018-01-19
US20160368884A1 (en) 2016-12-22
EA201792262A1 (ru) 2018-04-30
IL255466B (en) 2022-07-01
EA032363B1 (ru) 2019-05-31
ES2709362T3 (es) 2019-04-16
BR112017024039A2 (pt) 2018-07-24
TW201706255A (zh) 2017-02-16
EP3294719B1 (fr) 2019-01-02
KR102551429B1 (ko) 2023-07-04
CA2984615A1 (fr) 2016-11-17
PL3294719T3 (pl) 2019-04-30
TN2017000453A1 (en) 2019-04-12
HRP20190089T1 (hr) 2019-02-22
CY1121171T1 (el) 2020-05-29
HK1252099B (zh) 2020-02-07
SV2017005560A (es) 2018-02-23
MY184965A (en) 2021-04-30
RU2713889C2 (ru) 2020-02-10
UA120779C2 (uk) 2020-02-10
TR201901228T4 (tr) 2019-02-21
JP6731001B2 (ja) 2020-07-29
MX2017014390A (es) 2018-03-23
TWI700276B (zh) 2020-08-01
ECSP17074919A (es) 2018-02-28
PH12017502028A1 (en) 2018-04-02
JO3456B1 (ar) 2020-07-05
CR20170506A (es) 2018-02-08
AU2016259762B2 (en) 2020-03-19
BR112017024039B1 (pt) 2023-07-04
JP2018515520A (ja) 2018-06-14
CL2017002844A1 (es) 2018-05-11
AU2016259762A1 (en) 2017-11-16
GEP20197020B (en) 2019-09-25
PT3294719T (pt) 2019-02-07
IL255466A (en) 2018-01-31
RS58263B1 (sr) 2019-03-29
ZA201707337B (en) 2019-02-27
LT3294719T (lt) 2019-02-11
WO2016180870A1 (fr) 2016-11-17
CO2017011295A2 (es) 2018-02-20
CN107567440A (zh) 2018-01-09
CN107567440B (zh) 2021-06-22
CA2984615C (fr) 2023-06-13
DOP2017000260A (es) 2018-02-28
US10287261B2 (en) 2019-05-14
HK1252099A1 (zh) 2019-05-17
RU2017139002A (ru) 2019-06-13
RU2017139002A3 (fr) 2019-08-30
EP3294719A1 (fr) 2018-03-21
PE20180039A1 (es) 2018-01-09
BR112017024039B8 (pt) 2023-10-31
AR104591A1 (es) 2017-08-02
HUE042893T2 (hu) 2019-07-29

Similar Documents

Publication Publication Date Title
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331869T3 (da) Muscarinagonister
DK3305788T3 (da) Janus-kinase-hæmmer
DK3277719T3 (da) Polypeptider
DK3360890T3 (da) Genterapi
DK3331528T3 (da) Muskarinagonister
DK3331529T3 (da) Muskarinagonister
DK3310450T3 (da) Olie-vand-separator
DK3270930T3 (da) Præeklampsi
DK3394281T3 (da) Gærcelle
MA43397A (fr) Pyroglutamate de vortioxetine
DK3292136T3 (da) Penicillin-g-acylaser
DE112015006486A5 (de) Inkubationsrinne
DK3274482T3 (da) Stenborsknop
DK3318308T3 (da) Badmintonketsjer
DE112015005898A5 (de) Gurtschlossbringer
DE112016005599A5 (de) Strahlungsgrill
ES1140083Y (es) Descompatactador tetrafunción
DE102015206660A8 (de) Plattenaufteilanlage
DE112016001124A5 (de) Spannschutz
FI11070U1 (fi) Kantojyrsin
DE102015000551A8 (de) Rotationszerstäuberturbine
CU20150012S4 (es) Tenaza de soldar
DE102015226549B8 (de) Hybridheizmodul
UA32883S (uk) Пензель-макловиця